Array rises on triplet response data in pretreated mCRC

Array BioPharma Inc. (NASDAQ:ARRY) gained $2.42 (19%) to $15.56 Monday after reporting updated response data for a combination regimen of encorafenib (LGX818), binimetinib (MEK162)

Read the full 241 word article

User Sign In